Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Drug treatment for Alzheimer's disease: the way forward.

Maidment I, Fox C, Livingston G, Katona C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):6-8. No abstract available.

PMID:
16353163
2.

[Drug therapy of Alzheimer's disease using neurotransmitter-related substances].

Nakamura S.

Nihon Rinsho. 1988 Jul;46(7):1580-5. Japanese. No abstract available.

PMID:
2906095
3.

Development of memory-enhancing agents in the treatment of Alzheimer's disease.

Abernethy DR.

J Am Geriatr Soc. 1987 Oct;35(10):957-8. No abstract available.

PMID:
2888798
4.

Combination therapy no advantage in Alzheimer's treatment.

[No authors listed]

Harv Health Lett. 2012 Jun;37(8):8. No abstract available.

PMID:
22774260
5.

[New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].

Frölich L, Schmitt B, Calabrese P, Diener H, Förstl H, Gertz HJ, Hallauer JF, Hampel H, Ihl R, Rieke K, Riepe M, Supprian T.

Dtsch Med Wochenschr. 2005 Feb 25;130(8):408-12. Review. German. No abstract available.

PMID:
15717252
6.

Therapeutic approaches to Alzheimer's disease. An informal survey of promising drug discovery strategies.

Schehr RS.

Biotechnology (N Y). 1994 Feb;12(2):140-4. No abstract available.

PMID:
7765319
7.

Current Alzheimer's medications: effective treatment options, or expensive bottles of hope?

Vann AS.

J Am Med Dir Assoc. 2013 Jul;14(7):525-6. doi: 10.1016/j.jamda.2013.03.017. Epub 2013 May 9. No abstract available.

PMID:
23664019
8.

People with Alzheimer's disease are denied drugs.

Scott H.

Br J Nurs. 2000 Nov 9-22;9(20):2120. No abstract available.

PMID:
12271179
9.

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.

Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P.

Int J Geriatr Psychiatry. 2008 Sep;23(9):979-81. doi: 10.1002/gps.1979. No abstract available.

PMID:
18229874
10.

The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?

Schneider LS.

Int J Geriatr Psychiatry. 2006 Jan;21(1):9-13. No abstract available.

PMID:
16353164
11.

Alzheimer's disease biomarkers.

Chiu HF, Li SW.

Hong Kong Med J. 2012 Aug;18(4):351-2; author reply 352. No abstract available.

12.

[New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005].

Wellhöfer B.

Dtsch Med Wochenschr. 2006 Feb 10;131(6):284. German. No abstract available.

PMID:
16463237
13.

Drugs for Alzheimer disease.

[No authors listed]

Can Fam Physician. 2005 Nov;51:1485. English, French. No abstract available.

14.

[Alzheimer's disease].

Jedidi H, Jedidi Z, Salmon E.

Rev Med Liege. 2010 Mar;65(3):163-8. French.

15.

I remember.

Ladouceur R.

Can Fam Physician. 2006 Feb;52:155. English, French. No abstract available.

16.

The treatment of mild Alzheimer's disease post-NICE.

Connelly PJ, Passmore AP, Lawlor BA.

Int J Geriatr Psychiatry. 2007 Dec;22(12):1262-3. No abstract available.

PMID:
17503543
17.

NICE recommends drugs for moderate Alzheimer's disease.

Mayor S.

BMJ. 2006 Jan 28;332(7535):195. No abstract available.

18.

[An update on the pharmacological treatment of Alzheimer disease].

Fuentes P, Slachevsky A.

Rev Med Chil. 2005 Feb;133(2):224-30. Epub 2005 Apr 7. Review. Spanish.

19.

[Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil].

Creţu O, Szalontay AS, Chiriţă R, Chiriţă V.

Rev Med Chir Soc Med Nat Iasi. 2008 Jul-Sep;112(3):641-5. Romanian.

PMID:
20201245
20.

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Bosanquet N, Yeates A.

Pharmacoeconomics. 2006;24(6):623-5; author reply 625-6. No abstract available.

PMID:
16761908

Supplemental Content

Support Center